MedTrace Logo

Tenecteplase Pulmonary Embolism Italian Study

NCT00222651 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2008-05-06

No results posted yet for this study

Summary

To assess the efficacy and safety of Tenecteplase versus Placebo in normotensive patients with sub-massive Pulmonary Embolism and Right Ventricular Dysfunction (RVD) all receiving unfractionated heparin (UFH)

Conditions

Interventions

DRUG

tenecteplase

Sponsors & Collaborators

  • University Of Perugia

    lead OTHER

Principal Investigators

  • Giancarlo Agnelli, MD · Department of Internal Medicine - University of Perugia

  • Cecilia Becattini, MD · Department of Internal Medicine - University of Perugia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Completion
2006-07-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00222651 on ClinicalTrials.gov